EichorEICHOR
Location: Macquarie Park Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Macquarie Park

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Eli Lilly and Company · NCT07218380Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Merck Sharp & Dohme LLC · NCT06393374This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Pfizer · NCT06758401Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · Pfizer · NCT07421700EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Boehringer Ingelheim · NCT06531824A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0
Phase 3 · Merck Sharp & Dohme LLC · NCT07489495A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · AbbVie · NCT04928846A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1 · Janssen Research & Development, LLC · NCT05818683Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Merck Sharp & Dohme LLC · NCT03486873Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Phase 3 · Merck Sharp & Dohme LLC · NCT06136624A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Tr
Phase 3 · Merck Sharp & Dohme LLC · NCT06312176A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i
Phase 3 · Incyte Corporation · NCT07284849International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Phase N/A · Prostate Cancer Clinical Trials Consortium · NCT03151629Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Mirati Therapeutics Inc. · NCT04613596A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · Merck Sharp & Dohme LLC · NCT06966700A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · Merck Sharp & Dohme LLC · NCT06136650Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · Gilead Sciences · NCT05633654A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · Celgene · NCT06764485A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Phase 3 · Merck Sharp & Dohme LLC · NCT06925737A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1 · BeOne Medicines · NCT05981703Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small C
Phase 3 · Merck Sharp & Dohme LLC · NCT06170788A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · Amgen · NCT05920356A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Phase 1 · Jiangsu HengRui Medicine Co., Ltd. · NCT07711184A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High
Phase 3 · Macquarie University · Stemline Therapeutics, Inc. · NCT06492616A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal
Phase 3 · Shanghai Henlius Biotech · NCT06532006A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · Macquarie University · Frontier Medicines Corporation · NCT06244771RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati
Phase 2/Phase 3 · Macquarie University Hospital · Hoffmann-La Roche · NCT07413939
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.